Ivax Paxene Second-Line Indication Reflects Comparison To Doxil/DaunoXome
Executive Summary
The second-line Kaposi's sarcoma indication for Ivax' paclitaxel brand Paxene in the European Union appears to be based on a balancing of potentially superior response rates against a potentially greater risk of neutropenia, the European Public Assessment Report indicates.
You may also be interested in...
Bristol Taxol Three-Hour Infusion Patent Not Novel - U.K. Patents Court
The public dissemination of safety data from Phase I and Phase II trials of Bristol-Myers Squibb's Taxol (paclitaxel) render the company's three-hour infusion patent for the oncologic drug "obvious," a U.K. patent court has ruled.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials